Prospects and prejudices of human papillomavirus vaccines in India (Q37154142)

18 August 2017

1 reference

title

Prospects and prejudices of human papillomavirus vaccines in India (English)

1 reference

18 August 2017

0 references

1 reference

Bhudev C Das

1

1 reference

18 August 2017

Showket Hussain

series ordinal

2

1 reference

18 August 2017

Vilas Nasare

series ordinal

3

1 reference

18 August 2017

Mausumi Bharadwaj

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

14 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

26

1 reference

18 August 2017

issue

22

1 reference

18 August 2017

page(s)

2669-2679

1 reference

Human papilloma viruses (HPV): Characterization of four different isolates

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

7 January 2021

Viruses in human cancers

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

HPV infections and oesophageal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Global cancer statistics, 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Chapter 1: HPV in the etiology of human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Classification of papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

A high frequency of human papillomavirus DNA sequences in cervical carcinomas of indian women as revealed by southern blot hybridization and polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Chapter 6: Epidemiology and transmission dynamics of genital HPV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

A comparative profile of the prevalence and age distribution of human papillomavirus type 16/18 infections among three states of India with focus on northeast India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Human papillomavirus (HPV) DNA detection in self-collected urine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

The promise of global cervical-cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Quadrivalent human papillomavirus recombinant vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Immune responses to human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Prophylactic human papillomavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Prevention of cervical cancer through papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

HPV vaccines: the beginning of the end for cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Costs of scaling up health interventions: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

A human papillomavirus type 16 vaccine by oral delivery of L1 protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

7 January 2021

Immunization with DNA.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

DNA vaccines: designing strategies against parasitic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Progress toward an elusive goal: current status of cytomegalovirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

DNA vaccines: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Recent developments in tuberculosis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

DNA vaccines for cervical cancer: from bench to bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Papillomaviruses and cancer: from basic studies to clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

PUBLIC HEALTH: High Hopes and Dilemmas for a Cervical Cancer Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2008.03.056

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.03.056

1 reference

18 August 2017

1 reference